The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.

Autor:	Shah NJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical Center, New York, NY, USA., Patel VG; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Zhong X; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Pina L; Department of Medicine, Columbia University Medical Center, New York, NY, USA., Hawley JE; Department of Medicine, Columbia University Medical Center, New York, NY, USA., Lin E; Department of Medicine, Montefiore Center for Cancer Care, Bronx, NY, USA., Gartrell BA; Department of Medicine, Montefiore Center for Cancer Care, Bronx, NY, USA., Febles VA; Department of Medicine, NYU Langone Medical Center, New York, NY, USA., Wise DR; Department of Medicine, NYU Langone Medical Center, New York, NY, USA., Qin Q; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Mellgard G; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Joshi H; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Nauseef JT; Department of Medicine, Weill Cornell Medical Center, New York, NY, USA., Green DA; Department of Medicine, Weill Cornell Medical Center, New York, NY, USA., Vlachostergios PJ; Department of Medicine, Weill Cornell Medical Center, New York, NY, USA., Kwon DH; Department of Medicine, University of California, San Francisco, CA, USA., Huang F; Department of Medicine, University of California, San Francisco, CA, USA., Liaw B; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Tagawa S; Department of Medicine, Weill Cornell Medical Center, New York, NY, USA., Kantoff P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical Center, New York, NY, USA., Morris MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical Center, New York, NY, USA., Oh WK; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jazyk:	angličtina
Zdroj:	JNCI cancer spectrum [JNCI Cancer Spectr] 2022 May 02; Vol. 6 (3).
DOI:	10.1093/jncics/pkac035
Abstrakt:	Background: TMPRSS2, a cell surface protease regulated by androgens and commonly upregulated in prostate cancer (PCa), is a necessary component for SARS-CoV-2 viral entry into respiratory epithelial cells. Previous reports suggested a lower risk of SARS-CoV-2 among PCa patients on androgen deprivation therapy (ADT). However, the impact of ADT on severe COVID-19 illness is poorly understood. Methods: We performed a multicenter study across 7 US medical centers and evaluated patients with PCa and SARS-CoV-2 detected by polymerase-chain-reaction between March 1, 2020, and May 31, 2020. PCa patients were considered on ADT if they had received appropriate ADT treatment within 6 months of COVID-19 diagnosis. We used multivariable logistic and Cox proportional-hazard regression models for analysis. All statistical tests were 2-sided. Results: We identified 465 PCa patients (median age = 71 years) with a median follow-up of 60 days. Age, body mass index, cardiovascular comorbidity, and PCa clinical disease state adjusted overall survival (hazard ratio [HR] = 1.16, 95% confidence interval [CI] = 0.68 to 1.98, P = .59), hospitalization status (HR = 0.96, 95% CI = 0.52 to 1.77, P = .90), supplemental oxygenation (HR 1.14, 95% CI = 0.66 to 1.99, P = .64), and use of mechanical ventilation (HR = 0.81, 95% CI = 0.25 to 2.66, P = .73) were similar between ADT and non-ADT cohorts. Similarly, the addition of androgen receptor-directed therapy within 30 days of COVID-19 diagnosis to ADT vs ADT alone did not statistically significantly affect overall survival (androgen receptor-directed therapy: HR = 1.27, 95% CI = 0.69 to 2.32, P = .44). Conclusions: In this retrospective cohort of PCa patients, the use of ADT was not demonstrated to influence severe COVID-19 outcomes, as defined by hospitalization, supplemental oxygen use, or death. Age 70 years and older was statistically significantly associated with a higher risk of developing severe COVID-19 disease. (© The Author(s) 2022. Published by Oxford University Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu